ANI Pharmaceuticals Inc. (ANIP) exhibits 45.0% gross margins and 16.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 13.7x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 12.6% operating margin and 16.0% ROIC, outpacing sector cost of capital.
ROIC: 16.0% // GM: 45.0%YoY revenue trajectory of +43.8% paired with 10.20% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +43.8% // FCF YLD: 10.20%Altman Z-Score of 2.36 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.36 // F-SCORE: 8/9Trading at 21.5x trailing P/E (18.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 21.5x // EV/EBITDA: 13.7xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $73.16 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.8% net margins.
NET MARGIN: 8.8% // D/E: 0.54x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ANIP & activate live FRED threshold breach alerts.